Spots Global Cancer Trial Database for advanced malignancy
Every month we try and update this database with for advanced malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas | NCT01231347 | Adenocarcinoma ... Advanced Solid ... Cancer Cancer of Pancr... Cancer of the P... Metastases Metastatic Canc... Metastatic Panc... Pancreas Cancer Pancreatic Canc... Bone Metastases Endocrine Cance... Oncology Oncology Patien... Solid Tumors Advanced Malign... | AMG 479 Placebo AMG 479 gemcitabine | 18 Years - | NantCell, Inc. | |
| A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | NCT02016729 | Advanced Malign... Cancer Oncology Oncology Patien... Acute Myeloid L... | AMG 232 Trametinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Study of IBI318 in Participants With Advanced Malignancies | NCT03875157 | Advanced Malign... | IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors | NCT00974896 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | AMG 479 | 18 Years - | NantCell, Inc. | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324323 | Hematologic Mal... Malignant Lymph... | Romidepsin Rifampin | 18 Years - | Celgene | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | NCT01723020 | Advanced Malign... Advanced Solid ... Cancer Oncology Oncology Patien... Tumors Glioblastoma Multiple Myelom... | AMG 232 | 18 Years - | Kartos Therapeutics, Inc. | |
| Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies | NCT00024648 | Neoplasms | LErafAON | 18 Years - | INSYS Therapeutics Inc | |
| A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors | NCT00858377 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | Arm 1- Dose Esc... Arm 1- Dose Exp... | 18 Years - | Amgen | |
| Regorafenib and Cetuximab in Patients With Advanced Malignancy | NCT02095054 | Advanced Cancer... | Regorafenib Cetuximab Questionnaire | 12 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors | NCT02508441 | Advanced Unrese... | Andes-1537 for ... | 18 Years - | Andes Biotechnologies | |
| Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days | NCT00024674 | Neoplasms | SS1(dsFv)-PE38 | 18 Years - | INSYS Therapeutics Inc | |
| QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors | NCT00974896 | Advanced Malign... Advanced Solid ... Cancer Solid Tumors Tumors | AMG 479 | 18 Years - | NantCell, Inc. | |
| Study of TP-3654 in Patients With Advanced Solid Tumors | NCT03715504 | Advanced Solid ... | TP-3654 | 18 Years - | Sumitomo Pharma America, Inc. | |
| Bevacizumab and Bortezomib in Patients With Advanced Malignancy | NCT00428545 | Advanced Malign... Lymphoma Myeloma Solid Tumors | Bevacizumab Bortezomib | - | M.D. Anderson Cancer Center | |
| Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy | NCT02925000 | Cancer | TLC178 | 18 Years - | Taiwan Liposome Company | |
| A Study of AMG 337 in Subjects With Advanced Solid Tumors | NCT01253707 | Advanced Malign... Advanced Solid ... Cancer Oncology Oncology Patien... Tumors | AMG 337 | 18 Years - | Amgen | |
| A Study of AMG 820 in Subjects With Advanced Solid Tumors | NCT01444404 | Advanced Malign... Advanced Solid ... Cancer Oncology Oncology Patien... Tumors | AMG 820 | 18 Years - | AmMax Bio, Inc. | |
| Study of TP-3654 in Patients With Advanced Solid Tumors | NCT03715504 | Advanced Solid ... | TP-3654 | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Study of AMG 820 in Subjects With Advanced Solid Tumors | NCT01444404 | Advanced Malign... Advanced Solid ... Cancer Oncology Oncology Patien... Tumors | AMG 820 | 18 Years - | AmMax Bio, Inc. | |
| Study of IBI318 in Participants With Advanced Malignancies | NCT03875157 | Advanced Malign... | IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 IBI318 | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors | NCT02743637 | Advanced Malign... Advanced Solid ... Neoplasm Metastasis | SDX-7320 | 21 Years - 85 Years | SynDevRx, Inc. | |
| A Study of Anlotinib in Subjects With Advanced Malignancy | NCT04216082 | Advanced Malign... | Anlotinib | 18 Years - 70 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials | NCT00949390 | Advanced Cancer | Questionnaire | - | M.D. Anderson Cancer Center | |
| Study of Vemurafenib, Carboplatin, and Paclitaxel | NCT01636622 | Advanced Cancer... | Vemurafenib Carboplatin Paclitaxel | 12 Years - | M.D. Anderson Cancer Center | |
| FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib | NCT01143779 | Advanced Cancer | FLT-PET | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | NCT02048488 | Solid Tumors Lymphomas | TSR-011 | 18 Years - | Tesaro, Inc. | |
| A Study of AMG 820 in Subjects With Advanced Solid Tumors | NCT01444404 | Advanced Malign... Advanced Solid ... Cancer Oncology Oncology Patien... Tumors | AMG 820 | 18 Years - | AmMax Bio, Inc. | |
| Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials | NCT00949390 | Advanced Cancer | Questionnaire | - | M.D. Anderson Cancer Center | |
| AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | NCT00147225 | Solid Tumors Advanced Cancer | AMG 531 Carboplatin Adriamycin Ifosfamide | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies | NCT00978926 | Advanced Malign... | 21 Years - | National University Hospital, Singapore | ||
| Study of Vemurafenib, Carboplatin, and Paclitaxel | NCT01636622 | Advanced Cancer... | Vemurafenib Carboplatin Paclitaxel | 12 Years - | M.D. Anderson Cancer Center | |
| A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | NCT02016729 | Advanced Malign... Cancer Oncology Oncology Patien... Acute Myeloid L... | AMG 232 Trametinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer | NCT01324310 | Hematologic Mal... Malignant Lymph... | Romidepsin Ketoconazole | 18 Years - | Celgene | |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | NCT03604783 | Advanced Solid ... Sarcoma Ewing Sarcoma Dedifferentiate... Synovial Sarcom... | TP-1287 | 12 Years - | Sumitomo Pharma America, Inc. | |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors | NCT03604783 | Advanced Solid ... Sarcoma Ewing Sarcoma Dedifferentiate... Synovial Sarcom... | TP-1287 | 12 Years - | Sumitomo Pharma America, Inc. | |
| A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies | NCT02978482 | Advanced Malign... | durvalumab tremelimumab + ... | 18 Years - 130 Years | AstraZeneca | |
| Study of TP-3654 in Patients With Advanced Solid Tumors | NCT03715504 | Advanced Solid ... | TP-3654 | 18 Years - | Sumitomo Pharma America, Inc. | |
| FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib | NCT01143779 | Advanced Cancer | FLT-PET | 18 Years - | M.D. Anderson Cancer Center | |
| Study of TP-3654 in Patients With Advanced Solid Tumors | NCT03715504 | Advanced Solid ... | TP-3654 | 18 Years - | Sumitomo Pharma America, Inc. | |
| A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors | NCT02743637 | Advanced Malign... Advanced Solid ... Neoplasm Metastasis | SDX-7320 | 21 Years - 85 Years | SynDevRx, Inc. | |
| A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma | NCT01723020 | Advanced Malign... Advanced Solid ... Cancer Oncology Oncology Patien... Tumors Glioblastoma Multiple Myelom... | AMG 232 | 18 Years - | Kartos Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
